United Therapeutics (UTHR) and Intermountain Health announced the world’s first patient treated in a clinical study of a bioengineered external liver assist product called miroliverELAP. This study is the first human clinical trial of a manufactured organ alternative.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics concludes enrollment in ADVANCE OUTCOMES study
- Buy Recommendation for United Therapeutics Based on Strong Market Position and Growth Potential
- United Therapeutics: Strong Market Position and Growth Potential Amidst Emerging Competition
- United Therapeutics price target lowered to $315 from $321 at BofA
- Morning Movers: Insmed jumps, United Therapeutics falls after TPIP study results